Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Borowitz

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Blood|February 4, 2010
Inactivation of LEF1 in T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Takaomi Sanda, Wenxue Ma, et al.
Cytometry. Part B, Clinical Cytometry|May 6, 2017
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced InterpretersMichael Keeney, Brent L Wood, Benjamin D Hedley, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Annals of Human Genetics|May 12, 2015
SVSI: fast and powerful set-valued system identification approach to identifying rare variants in sequencing studies for ordered categorical traitsWenjian Bi, Guolian Kang, Yanlong Zhao, et al.
Blood|October 5, 2011
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaNobuko Hijiya, Blythe Thomson, Michael S Isakoff, et al.
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology groupNyla A Heerema, Andrew J Carroll, Meenakshi Devidas, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Blood|February 4, 2010
Inactivation of LEF1 in T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Takaomi Sanda, Wenxue Ma, et al.
Cytometry. Part B, Clinical Cytometry|May 6, 2017
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced InterpretersMichael Keeney, Brent L Wood, Benjamin D Hedley, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Annals of Human Genetics|May 12, 2015
SVSI: fast and powerful set-valued system identification approach to identifying rare variants in sequencing studies for ordered categorical traitsWenjian Bi, Guolian Kang, Yanlong Zhao, et al.
Blood|October 5, 2011
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaNobuko Hijiya, Blythe Thomson, Michael S Isakoff, et al.
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology groupNyla A Heerema, Andrew J Carroll, Meenakshi Devidas, et al.
Pageof 15